Hi, Subscriber

Joel Embiid: Everything you need to know

Joel Embiid

Joel Embiid

#21 C
Philadelphia 76ers

Status

GTD - Abdomen - Surgery Expected Return: 2026-04-24

STATS

Joel Embiid

Joel Embiid Career Stats  

  • Career Averages

    PTS
    REB
    AST
    BLK
    STL
    24.9
    10.9
    3.1
    1.7
    0.8
    Year GP GS MIN PTS REB AST BLK STL TO DD2 TD3 3PM 3PA 3P% 2PM 2PA 2P% FGM FGA FG% FTM FTA FT% OREB DREB PF A/TO +/- TS%
    2023-24 6 6 41.3 33.0 10.8 5.7 1.5 1.2 4.2 4 1 2.2 6.5 33.3% 7.7 15.7 48.9% 9.8 22.2 44.4% 11.2 13.0 85.9% 3.2 7.7 3.3 1.4 +46 59.2%
    2022-23 9 9 37.3 23.7 9.8 2.7 2.8 0.7 3.9 5 0 0.6 3.1 17.9% 6.8 13.9 48.8% 7.3 17.0 43.1% 8.4 9.3 90.5% 1.8 8.0 3.0 0.7 -6 56.1%
    2021-22 10 10 38.5 23.6 10.7 2.1 0.8 0.4 3.2 8 0 0.7 3.3 21.2% 7.1 12.8 55.5% 7.8 16.1 48.4% 7.3 8.9 82.0% 2.1 8.6 3.4 0.7 +28 59.0%
    2020-21 11 11 32.5 28.1 10.5 3.4 1.5 1.0 3.8 5 0 1.5 3.7 39.0% 7.7 14.2 54.5% 9.2 17.9 51.3% 8.3 9.9 83.5% 1.5 9.1 3.0 0.9 +121 63.1%
    2019-20 4 4 36.3 30.0 12.3 1.3 1.3 1.5 3.8 4 0 1.0 4.0 25.0% 7.5 14.5 51.7% 8.5 18.5 45.9% 12.0 14.8 81.4% 2.8 9.5 4.5 0.3 -53 60.0%
    2018-19 11 11 30.4 20.2 10.5 3.4 2.3 0.7 3.6 7 0 1.1 3.5 30.8% 5.1 10.9 46.7% 6.2 14.5 42.8% 6.7 8.2 82.2% 1.9 8.5 3.1 0.9 +143 55.9%
    2017-18 8 8 34.8 21.4 12.6 3.0 1.8 0.9 3.6 7 0 1.0 3.6 27.6% 6.5 13.6 47.7% 7.5 17.3 43.5% 5.4 7.6 70.5% 2.9 9.8 3.9 0.8 +43 51.9%
    Career
    59
    59
    35.3
    24.9
    10.9
    3.1
    1.7
    0.8
    3.7
    40
    1
    1.1
    3.8
    28.9%
    6.8
    13.4
    50.8%
    7.9
    17.2
    45.9%
    8.0
    9.7
    82.8%
    2.2
    8.7
    3.3
    0.8
    +322
    58.0%
Joel Embiid

Joel Embiid Game Log   2025-26

  • Regular Season
     
    Date
    Opp
    Result
    MIN
    PTS
    REB
    AST
    BLK
    STL
    TO
    3PA
    3PM
    3P%
    2PA
    2PM
    2P%
    FGA
    FGM
    FG%
    FTA
    FTM
    FT%
    OREB
    DREB
    A/TO
    +/-
    PF
    PER
    TS%
    4/6
    SAS
    L 115-102
    39
    34
    12
    1
    4
    0
    4
    6
    2
    33.3%
    13
    6
    46.2%
    19
    8
    42.1%
    19
    16
    84.2%
    5
    7
    0.3
    -7
    3
    40
    62.1%
    4/3
    MIN
    W 115-103
    34
    19
    13
    7
    3
    0
    1
    6
    1
    16.7%
    11
    5
    45.5%
    17
    6
    35.3%
    7
    6
    85.7%
    2
    11
    7.0
    +15
    3
    29
    47.3%
    3/30
    MIA
    L 119-109
    34
    26
    7
    3
    1
    0
    3
    6
    2
    33.3%
    19
    8
    42.1%
    25
    10
    40.0%
    5
    4
    80.0%
    1
    6
    1.0
    -18
    4
    15
    47.8%
    3/28
    CHA
    W 118-114
    35
    29
    6
    2
    2
    0
    0
    6
    3
    50.0%
    13
    5
    38.5%
    19
    8
    42.1%
    13
    10
    76.9%
    0
    6
    0.0
    +5
    0
    33
    58.7%
    3/25
    CHI
    W 157-137
    28
    35
    6
    7
    1
    0
    3
    3
    3
    100.0%
    14
    9
    64.3%
    17
    12
    70.6%
    9
    8
    88.9%
    0
    6
    2.3
    +33
    2
    44
    83.5%
    2/26
    MIA
    W 124-117
    31
    26
    11
    4
    0
    1
    2
    6
    2
    33.3%
    14
    6
    42.9%
    20
    8
    40.0%
    9
    8
    88.9%
    1
    10
    2.0
    +0
    1
    32
    54.3%
    2/24
    IND
    W 135-114
    26
    27
    6
    5
    1
    0
    4
    4
    1
    25.0%
    13
    10
    76.9%
    17
    11
    64.7%
    5
    4
    80.0%
    1
    5
    1.3
    -1
    2
    30
    70.3%
    2/7
    PHX
    W 109-103
    33
    33
    9
    3
    1
    0
    2
    7
    4
    57.1%
    12
    5
    41.7%
    19
    9
    47.4%
    13
    11
    84.6%
    1
    8
    1.5
    -10
    3
    35
    66.7%
    2/5
    LAL
    L 119-115
    38
    35
    7
    7
    2
    1
    3
    2
    1
    50.0%
    17
    12
    70.6%
    19
    13
    68.4%
    8
    8
    100.0%
    1
    6
    2.3
    +7
    2
    49
    77.7%
    2/2
    LAC
    W 128-113
    32
    24
    5
    3
    0
    1
    1
    2
    1
    50.0%
    17
    7
    41.2%
    19
    8
    42.1%
    7
    7
    100.0%
    0
    5
    3.0
    +2
    4
    22
    54.3%
    1/31
    NOP
    W 124-114
    39
    40
    11
    4
    2
    1
    5
    5
    3
    60.0%
    22
    10
    45.5%
    27
    13
    48.1%
    14
    11
    78.6%
    4
    7
    0.8
    +16
    2
    38
    60.3%
    1/29
    SAC
    W 113-111
    35
    37
    5
    8
    1
    1
    2
    2
    1
    50.0%
    19
    12
    63.2%
    21
    13
    61.9%
    13
    10
    76.9%
    0
    5
    4.0
    +9
    3
    44
    69.2%
    1/27
    MIL
    W 139-122
    29
    29
    9
    5
    0
    1
    2
    4
    1
    25.0%
    20
    10
    50.0%
    24
    11
    45.8%
    6
    6
    100.0%
    6
    3
    2.5
    +6
    2
    27
    54.4%
    1/24
    NYK
    L 112-109
    36
    38
    11
    5
    1
    0
    4
    5
    3
    60.0%
    16
    10
    62.5%
    21
    13
    61.9%
    12
    9
    75.0%
    3
    8
    1.3
    -3
    2
    45
    72.3%
    1/22
    HOU
    W 128-122
    45
    32
    15
    10
    1
    1
    5
    3
    1
    33.3%
    16
    9
    56.3%
    19
    10
    52.6%
    12
    11
    91.7%
    3
    12
    2.0
    +21
    1
    53
    65.9%
    1/19
    IND
    W 113-104
    33
    30
    9
    4
    0
    0
    1
    1
    1
    100.0%
    16
    9
    56.3%
    17
    10
    58.8%
    10
    9
    90.0%
    2
    7
    4.0
    +3
    1
    38
    70.1%
    1/16
    CLE
    L 117-115
    33
    33
    5
    3
    1
    0
    1
    3
    2
    66.7%
    19
    8
    42.1%
    22
    10
    45.5%
    12
    11
    91.7%
    3
    2
    3.0
    +9
    0
    34
    60.5%
    1/14
    CLE
    L 133-107
    24
    20
    4
    3
    1
    1
    6
    5
    2
    40.0%
    9
    5
    55.6%
    14
    7
    50.0%
    4
    4
    100.0%
    2
    2
    0.5
    -18
    0
    17
    63.5%
    1/12
    TOR
    W 115-102
    35
    27
    8
    4
    0
    2
    7
    6
    1
    16.7%
    11
    8
    72.7%
    17
    9
    52.9%
    8
    8
    100.0%
    2
    6
    0.6
    +12
    1
    28
    65.8%
    1/9
    ORL
    W 103-91
    31
    22
    9
    3
    1
    1
    4
    3
    0
    0.0%
    14
    7
    50.0%
    17
    7
    41.2%
    9
    8
    88.9%
    3
    6
    0.8
    +4
    2
    23
    52.5%
    1/7
    WAS
    W 131-110
    25
    28
    7
    2
    2
    0
    2
    2
    1
    50.0%
    12
    9
    75.0%
    14
    10
    71.4%
    8
    7
    87.5%
    0
    7
    1.0
    +27
    3
    33
    79.9%
    1/5
    DEN
    L 125-124
    40
    32
    10
    2
    1
    0
    6
    4
    1
    25.0%
    18
    12
    66.7%
    22
    13
    59.1%
    5
    5
    100.0%
    6
    4
    0.3
    +8
    2
    32
    66.1%
    1/3
    NYK
    W 130-119
    33
    26
    10
    5
    0
    0
    3
    1
    0
    0.0%
    14
    9
    64.3%
    15
    9
    60.0%
    12
    8
    66.7%
    2
    8
    1.7
    +9
    4
    31
    64.1%
    1/1
    DAL
    W 123-108
    35
    22
    4
    6
    1
    0
    2
    3
    0
    0.0%
    15
    9
    60.0%
    18
    9
    50.0%
    5
    4
    80.0%
    0
    4
    3.0
    +9
    1
    25
    54.5%
    12/30
    MEM
    W 139-136
    38
    34
    10
    8
    2
    1
    4
    6
    1
    16.7%
    22
    10
    45.5%
    28
    11
    39.3%
    12
    11
    91.7%
    5
    5
    2.0
    -5
    5
    34
    51.1%
    12/26
    CHI
    L 109-102
    32
    31
    5
    1
    1
    0
    2
    4
    2
    50.0%
    15
    8
    53.3%
    19
    10
    52.6%
    9
    9
    100.0%
    1
    4
    0.5
    +2
    2
    29
    67.5%
    12/23
    BKN
    L 114-106
    31
    27
    6
    4
    2
    0
    3
    1
    1
    100.0%
    12
    7
    58.3%
    13
    8
    61.5%
    12
    10
    83.3%
    1
    5
    1.3
    +1
    5
    33
    73.9%
    12/14
    ATL
    L 120-117
    30
    22
    14
    1
    2
    1
    3
    3
    1
    33.3%
    17
    7
    41.2%
    20
    8
    40.0%
    6
    5
    83.3%
    6
    8
    0.3
    -8
    2
    27
    48.6%
    12/12
    IND
    W 115-105
    31
    39
    9
    3
    0
    1
    3
    8
    2
    25.0%
    15
    10
    66.7%
    23
    12
    52.2%
    18
    13
    72.2%
    2
    7
    1.0
    +16
    3
    38
    63.1%
    12/7
    LAL
    L 112-108
    30
    16
    7
    2
    1
    1
    0
    6
    0
    0.0%
    15
    4
    26.7%
    21
    4
    19.0%
    8
    8
    100.0%
    2
    5
    0.0
    +11
    1
    12
    32.6%
    12/4
    GSW
    W 99-98
    25
    12
    6
    3
    1
    0
    3
    5
    0
    0.0%
    8
    5
    62.5%
    13
    5
    38.5%
    2
    2
    100.0%
    0
    6
    1.0
    +2
    1
    11
    43.2%
    11/30
    ATL
    L 142-134
    30
    18
    4
    2
    1
    1
    2
    3
    0
    0.0%
    11
    6
    54.5%
    14
    6
    42.9%
    8
    6
    75.0%
    1
    3
    1.0
    -11
    2
    16
    51.4%
    11/8
    TOR
    W 130-120
    25
    29
    6
    4
    1
    0
    2
    4
    1
    25.0%
    12
    9
    75.0%
    16
    10
    62.5%
    9
    8
    88.9%
    2
    4
    2.0
    +15
    3
    35
    72.6%
    11/4
    CHI
    L 113-111
    25
    20
    6
    2
    4
    3
    3
    6
    1
    16.7%
    15
    6
    40.0%
    21
    7
    33.3%
    6
    5
    83.3%
    2
    4
    0.7
    +1
    2
    17
    42.3%
    10/31
    BOS
    L 109-108
    25
    20
    6
    3
    2
    0
    4
    2
    1
    50.0%
    11
    5
    45.5%
    13
    6
    46.2%
    7
    7
    100.0%
    1
    5
    0.8
    +2
    2
    24
    62.2%
    10/28
    WAS
    W 139-134
    23
    25
    7
    5
    1
    0
    3
    6
    3
    50.0%
    11
    6
    54.5%
    17
    9
    52.9%
    6
    4
    66.7%
    3
    4
    1.7
    +9
    4
    24
    63.6%
    10/25
    CHA
    W 125-121
    20
    20
    2
    4
    0
    2
    4
    6
    3
    50.0%
    5
    4
    80.0%
    11
    7
    63.6%
    5
    3
    60.0%
    0
    2
    1.0
    -2
    0
    23
    75.8%
    10/22
    BOS
    W 117-116
    20
    4
    6
    2
    1
    0
    0
    4
    0
    0.0%
    5
    1
    20.0%
    9
    1
    11.1%
    2
    2
    100.0%
    1
    5
    0.0
    -16
    2
    4
    20.2%
    Regular Season Totals
    31.6
    26.9
    7.7
    3.9
    1.2
    0.6
    2.9
    4.2
    1.4
    33.3%
    14.2
    7.6
    53.5%
    18.3
    9.0
    48.9%
    8.8
    7.5
    85.4%
    2.0
    5.7
    1.4
    +155
    2.2
    32.8
    60.5%
Joel Embiid

Joel Embiid Player Profile  

Team Philadelphia 76ers
Birthdate 3/16/1994 (32)
Status ACT
HT/WT 7'0", 270 lbs
Draft Info 2014: Rd 1; Pk 3 (PHI)
Birthplace Yaounde,, CMR
Position C
College Kansas
Experience 9 seasons
2025 Salary $62,548,416

Career History

Philadelphia 76ers 2014-Present (12 seasons)

Joel Embiid: Breaking News

Doubtful for Game 3

Embiid (abdomen) is doubtful for Game 3 against the Celtics on Friday, Kyle Neubeck of AllPHLY.com reports. This is yet another small victory for Embiid, who was ruled out well ahead of both Game 1 and Game 2. While he's unlikely to step onto the court for Game 3, the big man has recently been given clearance to practice in a limited fashion, indicating that he's currently ramping up his basketball activities. Adem Bona has started the first two games of the series and figures to do so again Friday night.

Limited at practice

Embiid (abdomen) was a limited participant at Thursday's practice, Kyle Neubeck of AllPHLY.com reports. This is a small step in the right direction for Embiid, who was recently cleared to begin his strength and conditioning program. His status for Game 3 against Boston on Friday has yet to be determined, though it would be a surprise if he was cleared.

Officially ruled out for Game 2

Embiid (abdomen) has been ruled out for Game 2 of the Eastern Conference first-round series against Boston on Tuesday. Embiid began a strength and conditioning program Monday after undergoing a successful appendectomy April 10, though he will remain unavailable for Game 2, as expected. It remains unclear whether the big man will be available at any point in the series against Boston, and Philadelphia will continue leaning on Adem Bona and Andre Drummond in his absence.

Joel Embiid: More News

Sam Cassell Could Boost Interest From Warriors During 76ers-Celtics Series

Sam Cassell Could Boost Interest From Warriors During 76ers-Celtics Series

Nick Nurse Said Joel Embiid Participated in “More Than a Walkthrough”

Nick Nurse Said Joel Embiid Participated in “More Than a Walkthrough”

76ers Injury Report for Game 3 vs. Celtics Features Major Joel Embiid Update

76ers Injury Report for Game 3 vs. Celtics Features Major Joel Embiid Update

76ers’ Nick Nurse Makes Statement on Joel Embiid Before Game 3 vs Celtics

76ers’ Nick Nurse Makes Statement on Joel Embiid Before Game 3 vs Celtics

VJ Edgecombe Opens Up on Viral Wink After Historic 76ers Game

VJ Edgecombe Opens Up on Viral Wink After Historic 76ers Game

76ers Announce Major Joel Embiid News Before Game 3 vs Celtics

76ers Announce Major Joel Embiid News Before Game 3 vs Celtics

76ers Urged to Keep Joel Embiid Out vs Celtics After Big Win

76ers Urged to Keep Joel Embiid Out vs Celtics After Big Win

Philadelphia 76ers Land Jared McCain Replacement in First Round of 2026 NBA Mock Draft

Philadelphia 76ers Land Jared McCain Replacement in First Round of 2026 NBA Mock Draft

Ex-Celtics Star Makes Strong VJ Edgecombe Claim After 76ers Stunner

Ex-Celtics Star Makes Strong VJ Edgecombe Claim After 76ers Stunner

VJ Edgecombe Gets Strong Statement From 76ers Star Tyrese Maxey

VJ Edgecombe Gets Strong Statement From 76ers Star Tyrese Maxey

NBA Mock Draft 2026: Big Moves by Teams, Players

NBA Mock Draft 2026: Big Moves by Teams, Players

VJ Edgecombe Gets Honest on Injury in 76ers-Celtics Game 2

VJ Edgecombe Gets Honest on Injury in 76ers-Celtics Game 2

Jaylen Brown Makes VJ Edgecombe Statement After 76ers-Celtics Game 2

Jaylen Brown Makes VJ Edgecombe Statement After 76ers-Celtics Game 2

VJ Edgecombe Makes NBA History in 76ers Game 2 Win vs Celtics

VJ Edgecombe Makes NBA History in 76ers Game 2 Win vs Celtics

VJ Edgecombe Becomes Youngest Player to Achieve Rare Playoff Feat

VJ Edgecombe Becomes Youngest Player to Achieve Rare Playoff Feat

Joel Embiid Reacts to 76ers’ Massive Game 2 Win vs Celtics

Joel Embiid Reacts to 76ers’ Massive Game 2 Win vs Celtics

VJ Edgecombe Injury: 76ers Star Exits Game Immediately After Scary Fall vs Celtics

VJ Edgecombe Injury: 76ers Star Exits Game Immediately After Scary Fall vs Celtics

Jayson Tatum Makes Surprising 76ers Statement Before Game 2

Jayson Tatum Makes Surprising 76ers Statement Before Game 2

Philadelphia 76ers’ Rookie Class Receives Great Grade Thanks to V.J. Edgecombe

Philadelphia 76ers’ Rookie Class Receives Great Grade Thanks to V.J. Edgecombe

76ers Get Surprising Joel Embiid Injury Update Just Before Game 2 vs Celtics

76ers Get Surprising Joel Embiid Injury Update Just Before Game 2 vs Celtics

Joel Embiid Injury Update: When Will 76ers Star Return Against Celtics?

Joel Embiid Injury Update: When Will 76ers Star Return Against Celtics?

Philadelphia 76ers Injury Report For Game 2 vs. Celtics: Joel Embiid Remains Sidelined

Philadelphia 76ers Injury Report For Game 2 vs. Celtics: Joel Embiid Remains Sidelined

Philadelphia 76ers Receive Worrying Joel Embiid Update Before Celtics Game 2

Philadelphia 76ers Receive Worrying Joel Embiid Update Before Celtics Game 2

76ers Get Good Joel Embiid News After Blowout Loss vs Celtics

76ers Get Good Joel Embiid News After Blowout Loss vs Celtics

Former 76ers Standout Makes Strong Statement After Celtics Blowout

Former 76ers Standout Makes Strong Statement After Celtics Blowout

Jayson Tatum Reacts to 76ers Getting Trolled by Boston Crowd

Jayson Tatum Reacts to 76ers Getting Trolled by Boston Crowd

Nick Nurse Gets Brutally Honest About 76ers’ Game 1 Blowout Loss to Celtics

Nick Nurse Gets Brutally Honest About 76ers’ Game 1 Blowout Loss to Celtics

Charles Barkley Delivers Stiff Reality Check to 76ers vs Celtics

Charles Barkley Delivers Stiff Reality Check to 76ers vs Celtics

Philadelphia 76ers’ V.J. Edgecombe Reacts to Frustrating Postseason Debut

Philadelphia 76ers’ V.J. Edgecombe Reacts to Frustrating Postseason Debut

Celtics Blow Out 76ers in Game 1 as Boston Sends Loud Playoff Message

Celtics Blow Out 76ers in Game 1 as Boston Sends Loud Playoff Message

Joel Embiid: More News